As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.
14 Analysts have issued a Savara, Inc. forecast:
14 Analysts have issued a Savara, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -122 -122 |
37%
37%
|
|
| EBIT (Operating Income) EBIT | -122 -122 |
37%
37%
|
|
| Net Profit | -116 -116 |
41%
41%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
| Head office | United States |
| CEO | Matthew Pauls |
| Employees | 59 |
| Founded | 1995 |
| Website | savarapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


